Results 231 to 240 of about 23,063 (265)
Some of the next articles are maybe not open access.
A Transdermal Delivery System for Glipizide
Current Drug Delivery, 2006Glipizide is one of the most commonly prescribed drugs for treatment of type 2 diabetes. Oral therapy with glipizide comprises problems of bioavailability fluctuations and may be associated with severe hypoglycaemia and gastric disturbances. As a potential for convenient, safe and effective antidiabetic therapy, the rationale of this study was to ...
H O, Ammar +4 more
openaire +2 more sources
Iontophoretic Transdermal Delivery of Haloperidol
Pharmaceutical Development and Technology, 2006The in vitro iontophoretic transdermal delivery of haloperidol (HP) across pig skin was investigated. Anodal iontophoresis considerably increased HP skin penetration and accumulation as compared to the passive controls.The effect of NaCl and HP concentrations on the vehicle were also studied.
Alvarez Figueroa, María Javiera +2 more
openaire +3 more sources
Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design, 2015Proniosomes are liquid crystalline-compact niosomal hybrid that can be hydrated to form niosomal dispersion instantly before use. It is a promising drug carrier with better physical and chemical stability than niosomes. Proniosomes have the potential to be scaled up for industrial purposes.
Yahya, Rahimpour +2 more
openaire +2 more sources
Dermal and Transdermal Delivery: Prodrugs
Therapeutic Delivery, 2010Attempts to deliver drugs into and through the skin (dermal and transdermal delivery) have not been very successful because the physicochemical properties of drugs are often not optimal. Prodrugs can be used to optimize those physicochemical properties of drugs and optimize their delivery by transiently masking their polar functional groups. For a drug
Kenneth B, Sloan +2 more
openaire +2 more sources
2009
Transdermal drug delivery is a validated technology contributing significantly to global pharmaceutical care. Since 1980, impressive growth in this field has been observed with many commercial successes; importantly, a new chemical entity was recently developed and approved for transdermal administration without having first been given as an injectable
openaire +2 more sources
Transdermal drug delivery is a validated technology contributing significantly to global pharmaceutical care. Since 1980, impressive growth in this field has been observed with many commercial successes; importantly, a new chemical entity was recently developed and approved for transdermal administration without having first been given as an injectable
openaire +2 more sources
Pharmacokinetics of the transdermal delivery of benfotiamine
Acta Diabetologica, 2015Accumulation of advanced glycation endpoints is a trigger to the development of diabetic peripheral neuropathy, which is a common complication of diabetes. Oral administration of benfotiamine (BFT) has shown some preclinical and clinical promise as a treatment for diabetic peripheral neuropathy.
Zhen, Zhu +2 more
openaire +2 more sources
PLGA Nanoparticles and Transdermal Delivery
Recent Patents on Nanotechnology, 2023openaire +2 more sources
An investigation into the transdermal delivery of nifedipine
Pharmaceutica Acta Helvetiae, 1996A systematic attempt to develop a transdermal delivery system for nifedipine is presented. Measured physicochemical properties influencing percutaneous absorption such as solubility and partition coefficient confirmed the drug's potention for such a formulation approach.
D M, McDaid, P B, Deasy
openaire +2 more sources
Reflections on transdermal drug delivery
Pharmaceutical Science & Technology Today, 1999'It is better to be approximately right rather than precisely wrong.'
openaire +2 more sources
Transdermal delivery of dopaminergic agents
Neurology, 2005It has been more than 30 years since Calne et al.1 described the symptomatic effects of bromocriptine in patients with Parkinson’s disease. After this pioneering work, bromocriptine was the first dopamine (DA) agonist to be marketed for the treatment of Parkinson’s disease (PD). Since that time, at least eight other DA agonists have become available as
openaire +2 more sources